Crispr therapeutics ag CRSP.US 總覽分析
CRSP 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
CRSP 近期報酬表現
5.52%
Crispr therapeutics ag
1.31%
同產業平均
0.58%
S&P500
與 CRSP 同產業的標的表現
- BEAM Beam therapeutics inc價值 2 分趨勢 1 分波段 4 分籌碼 3 分股利 1 分查看更多
CRSP 公司資訊
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.